On September 4, 2018 Turnstone Biologics, a clinical-stage immuno-oncology company developing the next generation of oncolytic viral therapies, and the La Jolla Institute for Allergy and Immunology reported that they have entered into a collaboration and licensing agreement whereby Turnstone will utilize La Jolla Institute’s proprietary neoantigen identification methodology to select personalized neoantigens to target with its proprietary viral technologies for the development of new cancer immunotherapies (Press release, Turnstone Biologics, SEPT 4, 2018, View Source [SID1234529266]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, Turnstone will license the neoantigen identification methods developed by La Jolla Institute professors Dr. Stephen Schoenberger, Division of Developmental Immunology, and Dr. Bjoern Peters, Division of Vaccine Discovery, for use in cancer immunotherapies. Turnstone will fund collaborative research to further develop antigen identification methods for use in a Phase I/II clinical trial using its proprietary MG1 viral platform, expected to commence in 2019. Turnstone will also make development and regulatory milestone payments for therapies that utilize La Jolla Institute’s technology.
"Neoantigen-based treatments have the potential to transform cancer patient care by targeting specific genetic mutations in cancer malignancies," said Dr. Mike Burgess, MBChB, Ph.D., President of Research and Development of Turnstone. "Neoantigens identified using the highly-predictive functional-based approach developed at La Jolla Institute will be incorporated into our MG1 viral platform to form powerful immunotherapies. We are excited to be collaborating with the La Jolla Institute with the goal of developing best-in-class personalized cancer medicines."
"The field of neoantigens has evolved tremendously, and we are diligently working to more accurately predict patient-specific cancer mutations that can be targeted to drive more effective cancer treatments," says Dr. Stephen Schoenberger. "Turnstone has exciting proprietory technologies for eliciting strong anti-tumor immune responses and we are looking forward to capitalizing on their novel approach to bring personalized neoantigen therapies to patients."